The currently available pharmacological treatments for opioid addiction fall into one of two categories: opioid receptor agonists (i.e., methadone, buprenorphine, and buprenorphine/naloxone combination) and opioid receptor antagonists (i.e., naltrexone). Both psychiatrists and patients prefer opioid receptor agonists, of which Indivior’s Suboxone Film is the most widely prescribed branded agent in this market. However, the misuse and diversion potential associated with these treatments are an ongoing concern. Despite psychiatrists’ overall satisfaction with current therapies, they face a number of challenges treating this population, including very low compliance rates, which, in turn, contribute to high relapse rates among their opioid-addicted patients.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 U.S. psychiatrists
Key companies: Indivior, Orexo, BioDelivery Sciences, Alkermes
Key drugs: Suboxone Film, Subutex, Sublocade, Zubsolv, Bunavail, Probuphine, Vivitrol, methadone
Key insights provided: